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At a Glance Commentary: 
Scientific Knowledge on the Subject 
Through the systematic search of PubMed and Cochrane Library we identified 18 prospective 
studies, one meta-analysis and five recent in-depth reviews of urinary biomarkers of acute 
kidney injury in critically ill patients, published before January, 2014 (additional detail provided in 
the Supplement). Only one study prospectively compared all biomarkers against each other and 
found that the biomarker panel [TIMP-2]•[IGFBP7] had the highest area under the receiver-
operating characteristics curve for AKI. No prior study has prospective validated biomarker 
cutoffs nor used clinical adjudication as the gold standard for the endpoint.  
 
What This Study Adds to the Field 
This is the first report of a multi-center biomarker study that prospectively validates a pre-
defined biomarker cutoff value for risk assessment of acute kidney injury where the endpoint 
was determined by clinical adjudication of experts blinded to the results of the test. The urinary 
[TIMP-2]•[IGFBP7] test significantly improves risk assessment by stratifying patients into distinct 
risk categories, with a 7-fold increase in risk for patients with a [TIMP-2]•[IGFBP7] test value 
above the cutoff compared to those at or below. Furthermore, the [TIMP-2]•[IGFBP7] test 
provides substantial new information not available from the clinical variables known to be 
associated with AKI.  
 
This article has an online data supplement, which is accessible from this issues’s table of 
contents online at www.atsjournals.org.  
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Abstract 
Rationale. We recently reported two novel biomarkers for acute kidney injury (AKI), 
tissue inhibitor of metalloproteinases (TIMP)-2 and insulin-like growth factor binding protein 7 
(IGFBP7), both related to G1 cell cycle arrest.  
Objectives. We now validate a clinical test for urinary [TIMP-2]•[IGFBP7] at a high-
sensitivity cutoff > 0.3 for AKI risk stratification in a diverse population of critically ill patients. 
Methods. We conducted a prospective multicenter study of 420 critically ill patients. The 
primary analysis was the ability of urinary [TIMP-2]•[IGFBP7] to predict moderate to severe AKI 
within 12 hours. AKI was adjudicated by a committee of three independent expert nephrologists 
who were blinded to the results of the test.  
Measurements. Urinary TIMP-2 and IGFBP7 were measured using a clinical 
immunoassay platform. 
Main Results. The primary endpoint was reached in 17% of patients. For a single 
urinary [TIMP-2]•[IGFBP7] test, sensitivity at the pre-specified high-sensitivity cutoff of 0.3 
(ng/ml)2/1000 was 92% (95% CI 85%-98%) with a negative likelihood ratio of 0.18 (95% CI 0.06-
0.33). Critically ill patients with urinary [TIMP-2]•[IGFBP7] > 0.3 had seven times the risk for AKI 
(95% CI 4-22) compared to critically ill patients with a test result below 0.3. In a multivariate 
model including clinical information, urinary [TIMP-2]•[IGFBP7] remained statistically significant 
and a strong predictor of AKI (AUC 0.70, 95% CI 0.63-0.76 for clinical variables alone, versus 
AUC 0.86, 95% CI 0.80-0.90 for clinical variables plus [TIMP-2]•[IGFBP7]).  
Conclusions. Urinary [TIMP-2]•[IGFBP7] > 0.3 (ng/ml)2/1000 identifies patients at risk 
for imminent AKI.  
 Funding. Funded by Astute Medical. 
(ClinicalTrials.gov NCT01573962) 
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Introduction 
Acute kidney injury (AKI) occurs frequently in critically ill patients, is difficult to predict and 
adversely impacts short and long term clinical outcomes.1 These consequences include 
decreased survival;2 increased incidence of dialysis and chronic kidney disease (CKD);3 and 
markedly increased cost.4 We recently reported the discovery and independent validation of two 
G1 cell cycle arrest biomarkers for AKI, tissue inhibitor of metalloproteinases (TIMP)-2 and 
insulin-like growth factor binding protein (IGFBP)7.5 These markers demonstrated excellent 
ability to identify patients at risk of imminent (within 12 hours) AKI defined according to KDIGO 
(Kidney Disease: Improving Global Outcomes) criteria.6 Risk for major adverse kidney events 
(MAKE) including death, dialysis or persistent renal dysfunction also increased with increasing 
values of the test.5  
In order to guide the clinical use of the test for risk assessment, we selected a high-sensitivity 
cutoff using the results of our earlier studies.5,7 In the current prospective multicenter study we 
validate the [TIMP-2]•[IGFBP7] test for identifying patients at high risk for developing AKI in the 
next 12 hours. Unlike our prior studies, we assembled a clinical adjudication committee (CAC) 
composed of three expert clinical nephrologists to determine whether the primary endpoint of 
moderate to severe AKI was reached for each patient. Clinical adjudication, with experts 
examining all available information including patient outcomes, has been the standard approach 
for biomarker studies for many years. For clinical diagnoses such as AKI, where tissue 
diagnosis is usually prohibitive, clinical adjudication is the most rigorous standard.6,8 To our 
knowledge this is the first time such an approach has been used in determining the ability of a 
biomarker(s) to assess the risk for development of AKI.  
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Methods  
Study Design and Participants 
Topaz was a multicenter prospective study designed to validate the urinary [TIMP-2]•[IGFBP7] 
test to identify patients at high risk for imminent AKI. We enrolled 420 critically ill adult patients 
within 24 hours of admission to an intensive care unit (ICU) at 23 participating sites in the United 
States from May through December 2012 (Figure 1). All enrolled patients were considered 
critically ill due to significant respiratory or cardiovascular dysfunction (respiratory sequential 
organ failure assessment9 (SOFA) score ≥ 2 or cardiac SOFA score ≥ 1). The presence of an 
indwelling urinary catheter was also a prerequisite for inclusion. Patients with documented 
moderate to severe AKI (KDIGO6 stage 2 to 3) at the time of enrollment were excluded. Paired 
serum and urine samples for analysis of serum creatinine and the urinary [TIMP-2]•[IGFBP7] 
test were obtained immediately upon enrollment and then stored frozen until analysis. The 
primary end-point was the diagnosis of AKI within 12 hours of enrollment adjudicated by a CAC 
provided with all requested clinical data.  
Procedures 
Sample and data collection 
Urine and serum supernatants were frozen, shipped on dry ice, stored at -70°C and thawed 
immediately prior to analysis (see Supplement for additional details). All relevant clinical data 
including patient demographics, prior health history, reason for ICU admission, serum creatinine 
and hourly urine output were collected from the hospital records and stored using electronic 
case-report forms stored in an anonymized password-protected dataset residing on servers at 
independent sites (Medidata Solutions, New York, NY).  
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Adjudication of Acute Kidney Injury 
The final diagnosis of AKI was adjudicated by an expert CAC of three independent 
nephrologists who were blinded to the biomarker results. The basis for the adjudication was the 
KDIGO consensus criteria (based on RIFLE/AKIN definitions for AKI)6 corresponding to stages 
2-3 (moderate to severe). The adjudicators were asked to determine whether AKI was present 
or absent (defined as “AKI” or “no AKI”, respectively) within the 12 hours after enrollment using 
their expert judgment for each case. The CAC was provided all serum creatinine values for up 
to 6 months prior to enrollment and 72 hours after enrollment, all hourly urine output data 
available for up to 24 hours prior to enrollment and 72 hours after enrollment, daily fluid balance 
and use of diuretics. In addition, the date(s) of renal replacement therapy, death and ICU 
discharge were provided if occurring within the 72 hours after enrollment, as were age, sex, 
race, weight, reason for hospital and ICU admission and medical history. Additional information 
was provided to adjudicators if requested (see Supplement for additional details). If 
disagreement about the adjudication occurred, the majority determination was used although 
the adjudicators did not confer with each other.  
Biomarker Assays 
Urine samples were analyzed for TIMP-2 and IGFBP7 by technicians blinded to clinical data 
using a clinical immunoassay (NEPHROCHECK® Test and ASTUTE140® Meter, Astute Medical 
Inc, San Diego, CA; see the Supplementary Appendix) at three independent hospital 
laboratories (University of California at San Diego, University of Louisville, and ARUP 
Laboratories, Salt Lake City, UT). The ASTUTE140® Meter automatically multiplied the 
concentrations of the two biomarkers together and divided this product by 1000 to report a 
single numerical test result with units of (ng/ml)2/1000 (the units for all [TIMP-2]•[IGFBP7] test 
and cutoff values in this report) (Supplement Table E1-E2). Urine from each subject was 
analyzed at each of the three testing sites, producing triplicate test values for each sample. 
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Serum samples were analyzed for creatinine at a central lab (Center for Esoteric Testing [CET], 
Burlington, NC) using the IDMS-traceable Jaffe method (Roche COBAS Modular D instrument). 
Statistical Analysis 
The primary objective was to validate the urinary [TIMP-2]•[IGFBP7] test for AKI risk 
assessment based on the test’s ability to identify critically ill patients at high risk for imminent 
AKI occurring within 12 hours of test measurement. The primary analysis was sensitivity plus 
specificity > 1 for a [TIMP-2]•[IGFBP7] cutoff of 0.3, indicating that the [TIMP-2]•[IGFBP7] test is 
statistically informative. A target sample size of at least 400 evaluable subjects was selected for 
the study in order to achieve a minimum of 40 positive cases and provide greater than 95% 
power for the primary analysis. The predefined high-sensitivity test cutoff of 0.3 was determined 
using data from a previous study (Supplement Table E3). Secondary analyses included i) 
sensitivity and specificity at a predefined high-specificity cutoff of 2.0, and ii) examination of the 
relative risk for AKI in critically ill subjects stratified by either a single cutoff (0.3) or two cutoffs 
(0.3 and 2.0). Given the importance of sepsis as an etiology for AKI we also conducted a post-
hoc subgroup analysis restricting to patients with sepsis.  
Using multiple logistic regression we examined the performance of the [TIMP-2]•[IGFBP7] test 
with clinical covariates including enrollment serum creatinine. The multivariate model was 
constructed in a stepwise process. The first step was to assemble the list of clinical covariates 
as follows: any covariate that was reported to be associated (p < 0.1) with AKI by Kashani et al5 
were included; in addition, any of the susceptibilities or exposures defined in the KDIGO 
guideline6 or any new covariate that was associated (p < 0.1) with the primary endpoint in the 
Topaz critically ill cohort were included. The second step was to test all of these covariates in 
bivariate models with the [TIMP-2]•[IGFBP7] test result. The third step was to construct the 
multivariate model with all covariates that had a p < 0.1 in the bivariate models and that were 
not components of the non-renal APACHE III score (to avoid collinearity with the score). Overall, 
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collinearity between the variables in the multivariate model was assessed using Pearson 
correlation coefficients, which ranged from 0.02 to 0.22 in absolute value. Model performance 
was assessed with the Hosmer-Lemeshow test for goodness of fit. 
Statistical analyses were performed using SAS 9.2 (SAS Institute, Cary, NC) and R 3.010. For all 
analyses, two-sided p-values less than 0.05 or one-sided p-values less than 0.025 were 
considered statistically significant. Categorical variables were analyzed using Fisher Exact test, 
chi-square test, or logistic regression. All performance statistics (area under the receiver 
operating characteristic curve (AUC ROC), sensitivity, specificity and relative risk) were 
calculated as empirical estimates. To account for the correlation between the three [TIMP-
2]•[IGFBP7] test results per subject, confidence intervals (CI) were calculated using bootstrap 
sampling or closed-form variance equations for clustered binary data.11  
Role of the funding source  
The protocol was designed by the principal and co-principal investigators (JK, LC) in conjunction 
with the sponsor (Astute Medical, Inc) and met STROBE12 and STARD13 criteria. Data were 
collected by the investigators and analyzed by external statisticians (GD, JS, and MW). The first 
draft of the manuscript was written by the first author, with input from all other authors and the 
sponsor. The authors vouch for the accuracy and completeness of the data, the statistical 
analysis, and the fidelity of the study to the protocol. During the study, the investigators, 
participating institutions, and sponsors agreed to maintain data confidentiality. The protocol was 
approved by the Western Institutional Review Board (Olympia, Washington, USA) and 
institutional review board of each study site if requested. All patients or appropriate surrogates 
provided written informed consent. 
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Results 
Baseline characteristics  
The evaluable Topaz cohort included 408 adult critically ill patients from both surgical and 
medical ICUs (Figure 1). In Table 1, baseline characteristics for patients are shown separately 
for those developing and not developing AKI. Most of the patients presented with acute 
cardiovascular or respiratory dysfunction and sepsis at ICU admission (79%, 70% and 24%, 
respectively). A history of CKD was present in eight percent of the cohort. Additional exposures 
and susceptibilities for AKI, including use of radiocontrast (37%) and nephrotoxic medications 
(83%) preceding ICU admission were common.  
Adjudication of primary endpoint 
The primary endpoint was reached in 71 (17.4%) patients. The three adjudicators agreed on the 
diagnosis of AKI in 94% of cases. Fleiss' Kappa for multiple raters was 0.86 (95% CI 0.80-0.91, 
p<0.001), indicating excellent inter-rater reliability.  
Validation of urinary [TIMP-2]•[IGFBP7] test results  
Median time between ICU admission and sample collection for urinary [TIMP-2]•[IGFBP7] and 
serum creatinine was 15 hours (interquartile range 8-19 hours). Critically ill patients with a 
diagnosis of AKI within 12 hours had significantly higher median urinary [TIMP-2]•[IGFBP7] of 
1.6 (0.7-2.8) compared to 0.3 (0.2-0.8) for those without AKI (p<0.001) (Figure 2).  
Figure 3 shows the performance of a single measurement of the urinary [TIMP-2]•[IGFBP7] test 
to assess the risk for AKI within the subsequent 12 hours. The area under the receiver-
operating-characteristic curve (AUC) was 0.82 (95% CI 0.76-0.88). This result corroborates our 
prior findings from the Sapphire study where an AUC of 0.80 (95% CI 0.76-0.83) was observed.5 
When compared to simultaneously measured serum creatinine (AUC 0.63, 95% CI 0.56-0.70), 
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the urinary [TIMP-2]•[IGFBP7] test was superior (p<0.001) for assessing the risk of imminent 
AKI. 
For risk assessment using the urinary [TIMP-2]•[IGFBP7] test, we applied a preselected cutoff of 
0.3 as previously determined (Table E3).7 With single testing, the sensitivity for the urinary 
[TIMP-2]•[IGFBP7] test at the 0.3 cutoff was 92% (95% CI 85-98) with a specificity of 46% (95% 
CI 41-52) and combined sensitivity plus specificity of 1.38 (95%CI 1.30-1.46, p<0.001) (Figure 
3). Critically ill patients with urinary [TIMP-2]•[IGFBP7] test values > 0.3 had seven times the 
risk for AKI (95% CI 4-22) compared to those with a test value at or below the 0.3 cutoff (Figure 
4A). Only 1 in 27 patients (3.7% absolute risk) with a test result of 0.3 or less would manifest 
AKI within 12 hours, whereas more than 1 in 4 (27% absolute risk) above 0.3 would do so.   
The secondary analysis of the urinary [TIMP-2]•[IGFBP7] test at a preselected cutoff of 2.0 
(Table E3)7 demonstrated specificity of 95% (95% CI 93-97) and sensitivity of 37% (95% CI 26-
47) (Figure 3). When patients were stratified by both cutoffs, the relative risk for AKI increased 
proportionally. Compared to critically ill patients with a test result below 0.3, those with urinary 
[TIMP-2]•[IGFBP7] test between 0.3 and 2.0 had five times the risk for AKI (95% CI 3-17) while 
those with test results > 2.0 had 17 times the risk for AKI (95% CI 9-54) (Figure 4B).  
Addition of clinical information to biomarker test results 
All covariates that were significant in the bivariate logistic regression model with [TIMP-
2]•[IGFBP7] were included in the final multivariate model (Table 2). Urinary [TIMP-2]•[IGFBP7] 
remained a statistically significant and strong predictor of AKI when combined with the clinical 
model. The area under the curve of the combined urinary [TIMP-2]•[IGFBP7] test and clinical 
model of 0.86 (95%CI 0.80-0.90) was significantly (p<0.001) improved compared to the clinical 
model alone (AUC 0.70, 95%CI 0.63-0.76). In the sub-analysis of patients with sepsis urinary 
[TIMP-2]•[IGFBP7] test remained significant predictor of AKI (AUC 0.84, 95% 0.72-0.95).   
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Discussion 
To our knowledge this is the first study that prospectively validates a pre-defined cutoff value of 
a clinical test for risk assessment of AKI where the endpoint was determined by clinical 
adjudication of experts blinded to the results of the test. The Topaz study prospectively 
validated the urinary [TIMP-2]•[IGFBP7] test’s ability (at the 0.3 cutoff level) to identify critically ill 
patients at high risk for developing moderate to severe AKI within 12 hours. Clinical adjudication 
has been used in pivotal studies of biomarkers for other complex acute conditions such as acute 
decompensated heart failure14 and myocardial infarction15, but not for AKI. Importantly, all 
critically ill patients in our cohort were, by definition and clinical characteristics, at risk for AKI at 
study entry, but most of them (82.6%) did not develop AKI in the subsequent 12 hours. This 
observation illustrates the fact that in the presence of clinical risk factors for AKI like 
hypotension or hyoxemia, it is difficult to discriminate those who will imminently develop AKI 
from those who will not. Consequently widespread adoption of preventive interventions is 
unlikely in the absence of a test that reliably discerns those at increased risk from those at low 
risk. A similar challenge previously existed in the evaluation of patients with chest pain who are 
at risk for acute myocardial infarction, where only a minority of the patients with chest pain will 
actually have a myocardial infarction. Indeed this is why biomarkers for cardiac injury such as 
troponin are so useful in the evaluation of patients with chest pain. Similarly the commonly used 
Framingham Risk Score16 (based on clinical characteristics) places many individuals into an 
intermediate-risk category for coronary artery disease (CAD)17 where many cardiac events 
occur, treatment guidelines are unclear, and patients require further risk stratification.18 Not 
surpsringly, while fewer than 20% of physicians report using CAD risk calculators,19 nearly two-
thirds of physicians underestimate the risk using clinical judgment alone.20 The addition of 
biomarkers to clinical models has demonstrated increased accuracy for CAD risk assessment in 
the intermediate risk population21 and improved their clinical utility by physicans.22 Similarly, 
biomarkers are needed to help physicians further evaluate patients at risk for AKI. Amongst this 
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cohort of heterogeneous critically ill patients closely resembling general ICU population in the 
United States,23 the urinary [TIMP-2]•[IGFBP7] test at the 0.3 cutoff stratified risk for imminent 
AKI above and beyond clinical exposures and susceptibilities. Addition of the urinary [TIMP-
2]•[IGFBP7] test increased the AUC of the clinical model from 0.70 to 0.86 while stratifying 
patients in more distinct risk categories, with a 7-fold increase in risk for patients in the high risk 
group compared to those in the lowest.   
AKI remains one of the most common complications among hospitalized patients.1,24 Few risk 
stratification models based on clinical factors exist and they are generally inadequate in 
accurately identifying individual patients at risk.  Put simply, AKI does not hurt.  Thus, the ability 
to identify patients at risk for imminent AKI has been elusive and represents an important unmet 
need.25-27 The time window for intervention has been well demarcated for other acute conditions 
with high morbidity and mortality, including myocardial infarction (< 6 hours), stroke (< 3 hours) 
and severe trauma (< 1 hour).28-30 Although, no such timeframe has been identified for AKI, 
hampered in part by the lack of precise early diagnostic tools, there is consensus amongst AKI 
experts that identification of a similar (12-hour) time window for intervention for severe AKI is 
important.27  Large healthcare systems such as the National Health Service in the United 
Kingdom have systematically assessed the outcomes related to AKI, and found that delayed 
identification of patients with AKI contributes to worse outcomes.31 AKI is a significant public 
health hazard, and the prevalence of AKI has nearly doubled over the past decade.32,33 The 
associated morbidity is increasing, and AKI is becoming a significant cause of end-stage renal 
disease (ESRD), especially among younger patients.33,34  
The methodological strengths of this study include complete follow up for the primary endpoint, 
clinicians and investigators blinded to the results of the test and an adjudicated endpoint by 
experts in the field. Perhaps the greatest strength is that these results are highly generalizable 
and validate the preselected [TIMP-2]•[IGFBP7] cutoff for a consistent assessment of relative 
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risk for AKI that should remain stable regardless of underlying prevalence. This is a critical step 
in translating new biomarkers into routine practice because it provides clinicians with actionable 
information based on a positive or negative test result. The urinary [TIMP-2]•[IGFBP7] test has 
now been shown to provide early risk stratification for imminent AKI in over 1,000 critically ill 
patients in two multi-center studies enrolling diverse groups of patients with the prevalence of 
major exposures for AKI, such as sepsis, similar to other reports in the literature.5,35-38  
On the basis of these results, we conclude that the urinary [TIMP-2]•[IGFBP7] test can be used 
to identify critically ill patients at high risk for imminent AKI. This will enable early triage and risk 
stratification in a wide range of critically ill patients from the emergency room, acute admission 
areas and intensive care.  Early identification of these at-risk patients should improve delivery of 
KDIGO-recommended interventions and enable prompt interventional studies for the treatment 
of AKI in the not-so-distant future.  
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Figures 
 
Figure 1. Design of the Topaz study of critically ill subjects. aCritical illness was defined as 
admission to an ICU and sepsis-related organ failure assessment score9 ≥2 for respiratory 
and/or ≥1 for cardiovascular system. bUrine and Serum samples were stored at ≤-70oC until 
analysis. Subjects had to have an enrollment urine sample (but not a serum sample) to be 
considered evaluable (405 subjects had a study-specific enrollment serum sample). cCriteria for 
excluding samples were predefined prior to analysis. 
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Figure 2. Box plots of urinary [TIMP-2]•[IGFBP7] test values. Boxes and whiskers show 
inter-quartile ranges and total observed ranges (censored at 1.5 times the inter-quartile ranges), 
respectively. Subjects with AKI had significantly higher [TIMP-2]•[IGFBP7] test values than 
subjects without AKI (Wilcoxon rank sum test p<0.001). 
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Cutoff value, (ng/ml)2/1000 Sensitivity, % Specificity, % 
                       (95% CI) 
0.3 92 (85-98) 46 (41-52) 
2.0 37 (26-47) 95 (93-97) 
 
Figure 3. Urinary [TIMP-2]•[IGFBP7] test ROC curve for discriminating critically ill 
subjects with AKI (N = 71) from those with no AKI (N =337). 
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Figure 4. Relative risk of AKI in [TIMP-2]•[IGFBP7] test strata. AKI risk (A) in stratum with 
[TIMP-2]•[IGFBP7] values > 0.3 relative to risk in stratum ≤ 0.3, and (B) in strata with [TIMP-
2]•[IGFBP7] values (i) between 0.3 and 2.0 and (ii) > 2.0, relative to risk in stratum ≤ 0.3. P-
values < 0.002 for all pairwise strata comparisons. Error bars are 95% CI. 71 AKI subjects, 337 
no AKI. We observed an absolute risk in the ≤ 0.3 stratum of 3.7%; whereas above the 0.3 
cuttoff absolute risk was 27%. When two cutoffs are used absolute risk for the >0.3 ≤ 2.0 
stratum was 19% while above 2.0 absolute risk was 62%.  
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Table 1. Baseline characteristics 
 No AKI AKI All patients 
 
Patients, n (%) 337 (83%) 71 (17%) 408 
Age, years* 63 (17) 62 (16) 63 (17) 
Male 184 (55%) 35 (49%) 219 (54%) 
 
Race    
    Black 47 (14%) 9 (13%) 56 (14%) 
    White 280 (83%) 59 (83%) 339 (83%) 
    Other/Unknown 10 (3%) 3 (4%) 13 (3%) 
 
ICU Type    
    Cardiac Medical/Surgical 40 (12%) 8 (11%) 48 (12%) 
    Medical 149 (44%) 31 (44%) 180 (44%) 
    Mixed/Other 69 (20%) 14 (20%) 83 (20%) 
    Surgical/Trauma 79 (23%) 18 (25%) 97 (24%) 
 
Medical History    
    Body Mass Index, kg/m
2
† 28 (24-34) 31 (26-38) 28 (25-34) 
    Chronic Kidney Disease 27 (8%) 5 (7%) 32 (8%) 
    Diabetes Mellitus 92 (27%) 24 (34%) 116 (28%) 
    Congestive Heart Failure 67 (20%) 18 (25%) 85 (21%) 
    Coronary Artery Disease 100 (30%) 21 (30%) 121 (30%) 
    Hypertension 221 (66%) 50 (70%) 271 (66%) 
    Chronic Obstructive Pulmonary Disease 80 (24%) 10 (14%) 90 (22%) 
    Cancer 90 (27%) 19 (27%) 109 (27%) 
    Hematocrit < 30% 159 (47%) 25 (35%) 184 (45%) 
    Liver Disease 16 (5%) 8 (11%) 24 (6%) 
 
Acute Exposures and Susceptibilities    
    APACHE III Score (non-renal)†, ‡ 56 (44-75) 66 (49-87) 58 (44-78) 
    Cardiovascular dysfunction§ 261 (77%) 60 (85%) 321 (79%) 
    Respiratory dysfunction
¶
 231 (69%) 53 (75%) 284 (70%) 
    Sepsis
||
 75 (22%) 22 (31%) 97 (24%) 
    Radiocontrast agents 123 (36%) 28 (39%) 151 (37%) 
    Nephrotoxic drugs (at least 1)** 276 (82%) 61 (86%) 337 (83%) 
    Nephrotoxic drugs (at least 2)** 175 (52%) 32 (45%) 207 (51%) 
    Enrollment Serum Creatinine, mg/dL† 0.9 (0.7-1.2) 1.1 (0.8-1.5) 0.9 (0.7-1.3) 
 
*Mean (standard deviation); †median (interquartile range); ‡excludes serum creatinine, urine output and 
blood urea nitrogen; §cardiovascular SOFA ≥ 1; 
¶
respiratory SOFA ≥ 2; 
||
reason for ICU admission; 
**includes any of the following medications administered within 5 days prior to enrollment: nonsteroidal 
anti-inflammatory drugs, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, 
immunosuppressants, beta lactam antibiotics, aminoglycosides, vancomycin, acyclovir, amphotericin, 
allopurinol, colistin. 
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Table 2. Multivariate logistic regression model of clinical risk factors and the urinary [TIMP-
2]•[IGFBP7] testa 
Variableb 
Adjusted Odds Ratio (95% CI) 
Without Urinary 
[TIMP-2]•[IGFBP7] 
With Urinary [TIMP-
2]•[IGFBP7] 
Enrollment Serum Creatininec (per unit log) 2.36 (0.74-7.50) 2.45 (0.68-8.84) 
APACHE III Score (non-renal) (per unit) 1.02 (1.01-1.03)*** 1.02 (1.01-1.03)** 
Body Mass Index (per kg/m2) 1.05 (1.02-1.08)*** 1.07 (1.04-1.11)*** 
Urinary [TIMP-2]•[IGFBP7] testc (per unit log)  Not included 16.5 (7.6-35.5)*** 
Area under the curve (95% CI) 0.70 (0.63-0.76)*** 0.86 (0.80-0.90)*** 
aThe endpoint was a final diagnosis of AKI as shown in Figure 1; only the subjects who had a 
value recorded for all 4 variables in the model were included in the multivariate analysis (N = 
324 No AKI, 69 AKI, 393 total). bThe three AKI risk factors included in the multivariate model 
where those with p < 0.1 in bivariate logistic regression with the [TIMP-2]•[IGFBP7] test 
(performed for 17 risk factors including chronic kidney disease, sepsis and use of nephrotoxic 
agents, details presented in the Supplement). cLog10 transformation of the values measured in 
the enrollment samples were used in the model.**p<0.01, ***p<0.001. p = 0.45 and 0.36 for the 
Hosmer-Lemeshow goodness of fit test for the model without and with [TIMP-2]•[IGFBP7], 
respectively, which indicates good fit. 
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Topaz Study Sites and Personnel 
 
Topaz Principal Investigator: John A Kellum, MD 
Topaz Co-Principal Investigator: Lakhmir S Chawla, MD 
 
Topaz Study Enrolling Sites:  
California: Loma Linda University – H Bryant Nguyen, MD; Michael Terry, RCP; Jaenette Merrill-Henry, 
RCP; Deborah Dodge, RCP. University of California at Los Angeles – Eric Kleerup, MD. 
District of Columbia: George Washington University Medical Center – Danielle Davison, MD; Linda Shehu; 
Ermira Mitchell; Christina Seneff. 
Florida: Tampa General Hospital – Jason Wilson, MD. University of Florida – Azra Bihorac, MD; Philip 
Efron, MD; Adrian Agudelo; Hassan Alnuaimat, MD. 
Idaho: Eastern Idaho Medical Consultants, LLC – Kenneth Krell, MD; Amy Thornley, ACNP-BC; Kevin B 
Foster, CPhT. 
Illinois: Northwestern University – Richard Wunderink, MD; Helen Donnelly; Margaret Travis. University of 
Chicago – Jay Koyner, MD; Sharon Trevino, RN. 
Louisiana: Louisiana State University – Derrel D Graham, MD; Kimberley Hutchinson, RN. 
Maryland: University of Maryland School of Medicine – Matthew Lissauer, MD; Jessica Warren; Holly 
Howes. 
Michigan: University of Michigan – Michael Heung, MD; Anthony Courey, MD; Theresa Mottes, RN; 
Michigan Clinical Research Unit. 
Minnesota: Hennepin County Medical Center – James Miner, MD. 
Montana: The International Heart Institute of Montana – Richard Sellman, MD. 
North Carolina: Durham VA Medical Center – Andrew D Shaw, MD; S Becky Perfect; Elizabeth Rogers. 
New York: Montefiore Medical Center – Michelle Ng Gong, MD; Graciela Soto, MD; Miriam Martinez, RN; 
John Salcedo. Rochester General Medicine – Jim Szalados, MD; Linda Link, RN, BSN; Tia DeRosa, 
RN, ACNP. 
Ohio: Summa Health System Akron City Hospital – Scott T Wilber, MD; Bradley R Martin, MD; James A 
Wilson, MD; Jennifer A Frey, PhD, CCRP. 
Oregan: Portland VA Medical Center – Jennifer LeTourneau, DO; Kathy A Avalos, MA. 
Pennsylvania: AGH Nephrology Associates – Luis Ortega, MD; Donna Creese; Khaled Nashar, MD. 
University of Pittsburgh Medical Center – Ali Al-Khafaji, MD; Denise Scholl; Barb Early; Sarah Cua. 
Tennessee: Vanderbilt University School of Medicine – Wesley H Self, MD; Dayna Wyatt, RN; Charity 
Graves. 
Texas: Houston Methodist Medical Center – Janice L Zimmerman, MD; Deepa Bangalore, MD; Raul 
Sanchez Leon, MD. 
Virginia: Virginia Commonwealth University – Kyle Gunnerson, MD; Tamara Ponton, RN; Jennifer 
Chadbourne, RN. 
 
Topaz Study Measuring Sites: 
California: University of California at San Diego – Robert Fitzgerald, PhD; Nandkishor S Chindarkar; Eric C 
Warren; Antonio C Trammel. 
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Kentucky: University of Louisville – Saeed Jortani, PhD; William W Tucker; Louise Isaacs; Gina Thomson; 
Sanda Jones. 
Utah: ARUP Laboratories – Joely Straseski, PhD. 
 
Supplementary Methods  
Topaz Study 
Critically ill subjects in the Topaz study were enrolled at 23 clinical sites in the United States (see Figure 1 in the 
manuscript). Baseline and demographic information is shown in Table 1 of the manuscript. Entry and evaluability 
criteria were as follows: 
Inclusion Criteria 
a. Males and females 21 years of age or older; 
b. Subjects must be enrolled (first study-specific sample collection) within 24 hours of ICU admission; 
• Subjects enrolled from ED or Floor must be admitted to the ICU within 24 hours of enrollment;  
• Subjects enrolled in the ICU must have been admitted to the ICU or transferred into the study ICU 
from another ICU no more than 24 hours prior to enrollment; 
c. Expected to remain in the ICU for at least 48 hours after enrollment; 
d. Use of indwelling urinary catheter as standard care expected for at least 48 hours after enrollment; 
e. At least one of the following acute conditions documented within 24 hours prior to enrollment: 
• Respiratory SOFA score of ≥ 2 (PaO2/FiO2 <300);      
• Cardiovascular SOFA score of ≥ 1 (MAP < 70 mm Hg and/or any vasopressor required); 
f. Subject (or authorized representative) able and willing to provide written informed consent for study 
participation.   
Exclusion Criteria 
a. Special populations including women with known pregnancy, prisoners or institutionalized individuals; 
b. Previous renal transplantation; 
c. Known moderate to severe AKI prior to enrollment (e.g., RIFLE-I or RIFLE-F/ AKIN 2 or AKIN);  
d. Already receiving dialysis (either acute or chronic) or in imminent need of dialysis at the time of 
enrollment; 
e. Known infection with human immunodeficiency virus (HIV) or active hepatitis (acute or chronic); 
f. Subjects with a history of Chronic Kidney Disease (CKD) without a baseline serum creatinine value 
(baseline within 6 months of enrollment). 
Evaluability Criteria 
Subjects will be considered enrolled in the study when the enrollment (first) study–specific blood and urine samples 
are obtained. Subjects who terminate participation prior to that point will not be considered formally enrolled and 
may be replaced. 
A subject will be considered unevaluable for the primary purposes of this study if he/she does not have an 
indwelling urinary catheter and urine output data obtained through 30 hours after enrollment. For each draw time 
(enrollment and within 10-18 hours of enrollment) urine and serum samples collected more than 1 hour apart during 
a draw time will be considered unevaluable. Subjects discharged from the ICU prior to 30 hours in the study will be 
considered unevaluable. Subjects who expire prior to 48 hours in the study will be considered evaluable as long as 
he/she has study blood / urine samples obtained at enrollment and urine output data available through time of death. 
Subjects who were not already receiving kidney-related dialysis (either acute or chronic) or in imminent need of 
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dialysis at the time of enrollment, but who received kidney-related dialysis within 48 hours of enrollment will be 
considered evaluable. Subjects receiving non-kidney related dialysis or ultrafiltration within 12 hours of the first 
sample collection will be considered unevaluable; if non-kidney dialysis or ultrafiltration is initiated within 12 hours 
of collection of a second sample, that second sample will be considered non-evaluable. Subjects who are 
unevaluable will be withdrawn from the study. 
 
Laboratory Methods 
Blood and Urine Samples  
Study-specific blood samples were obtained via direct venipuncture, via other available venous access (e.g., an 
existing femoral sheath, central venous line, peripheral intravenous line, or hep-lock) or via an indwelling arterial 
line. Blood was collected in clot activator blood collection tubes (for serum). Serum was prepared by standard 
methods (centrifugation for 10 minutes at a minimum of 1,300 x g after clotting) and aliquots were frozen (on dry 
ice or liquid nitrogen) within two hours of collection. Samples were shipped on dry ice and stored at ≤ -70° C. 
Samples were thawed immediately prior to measurement. A blood sample was considered unevaluable for the study 
if: 
• It contained an insufficient volume (tube contains less than half of fill volume); 
• It was not collected in the proper type of blood collection tube; 
• The specimen was hemolyzed (i.e. a serum creatinine value cannot be obtained); 
• It was not properly labeled with a barcode label; 
• It was not collected within 60 minutes of the corresponding urine sample;  
• It was not processed within 120 minutes (2 hours) of sample collection; 
• It was not properly frozen at the site or upon arrival after shipping. 
 
Study-specific urine samples were collected in standard (non-coated) specimen cups. For subjects with indwelling 
bladder catheters, the collection bag was first emptied and then a fresh sample of urine collected; alternatively the 
sample could be taken from a urometer, if present. Samples were centrifuged (10 minutes at 1,000 x g) to remove 
any cells or other debris, and aliquots were frozen (on dry ice or liquid nitrogen) within 2 hours of collection. 
Samples were shipped on dry ice and stored at ≤ -70° C. Samples were thawed immediately prior to measurement. A 
urine sample was considered unevaluable if: 
• It was not collected within 60 minutes of the corresponding blood sample;  
• It was not processed and frozen within 120 minutes (2 hours) of sample collection; 
• There was less than 15 mL of sample; 
• It was not properly labeled with a barcode label; 
• It was not properly frozen upon arrival after shipping. 
After collection and processing, study-specific serum and urine samples were shipped to the study sponsor, who 
banked them and shipped them to the laboratories where they were analyzed. 
 
Assay Methods 
The biomarkers TIMP-2 and IGFBP7 were measured with the NEPHROCHECK
® 
Test (Astute Medical, San Diego, 
CA) at three independent hospital laboratories. The test is an in vitro diagnostic device that quantitatively measures 
IGFBP7 and TIMP-2 in human urine by fluorescence immunoassay on the ASTUTE140
® 
Meter. The test is a single-
use cartridge comprised of assays for the two biomarkers on a membrane test strip enclosed in a plastic housing that 
employs a sandwich immunoassay technique. The test procedure involves the operator applying a fresh or thawed 
(i.e. previously frozen) clinical urine sample (mixed with labeled fluorescent conjugate) to the test cartridge, and 
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then inserting the test cartridge into the meter for incubation, reading, result calculation, and result display in about 
20 minutes. The meter is a bench-top/table-top analyzer that converts the fluorescent signal from each of the two 
immunoassays into concentrations (of TIMP-2 and IGFBP-7) and computes and displays a single numerical test 
result equal to the product of the concentrations ([TIMP-2]•[IGFBP7]) in units of (ng/ml)
2
/1000. Concentration 
results for the assays are traceable to reference standard solutions that contain defined mass (concentration) of 
TIMP-2 and IGFBP-7 in accordance with EN ISO 17511.
E1
 Each test cartridge contains two detection zones used as 
internal controls (one positive and one negative control). These positive and negative controls are run automatically 
with every sample, in order to confirm the integrity of the test cartridge and the performance of the meter. If the 
automatic check of these internal controls shows that the control value results are not within pre-defined limits, the 
meter will display an error message and the test result will not be reported. These controls are in addition to external 
liquid controls (traceable to the same reference standard solutions as the test) which are run to verify test 
performance and operator proficiency. Data on the analytical characteristics of the test were obtained from the 
manufacturer are shown in Tables E1 and E2. The test and meter were not available for commercial sale in the 
United States at the time of manuscript submission. 
Enrollment serum samples were analyzed for serum creatinine at a central lab (Center for Esoteric Testing [CET], 
Burlington, NC) using the Jaffe method (Roche COBAS Modular D instrument) with IDMS-traceable calibration.  
 
Clinical Adjudication 
We recruited three noted experts in clinical nephrology to serve as adjudicators: 
 
Kathleen D. Liu, MD, PhD, MAS 
Associate Professor, Division of Nephrology and Critical Care 
Departments of Medicine and Anesthesia 
University of California, San Francisco 
 
Mitchell H. Rosner, MD, FACP 
Professor of Medicine, Division of Nephrology 
University of Virginia Health System 
 
Anitha Vijayan, MD 
Professor of Medicine, Renal Division 
Washington University School of Medicine in St. Louis 
 
These experts were independent of the sponsor and neither they nor their institutions participated in the sample 
collection or sample measurement studies. Adjudicators were paid for their work but had no other relationship with 
the sponsor. 
The procedures for adjudication were defined in advance of the study by consensus amongst the three adjudicators 
and the principal investigator in a series of face-to-face and teleconference meetings. Adjudicators collectively 
determined which variables would be extracted from the medical record and provided to them for adjudication. 
These variables included all serum creatinine values for up to 6 months prior to enrollment and 72 hours after 
enrollment, all hourly urine output data available for up to 24 hours prior to enrollment and 72 hours after 
enrollment, daily fluid balance and use of diuretics. In addition, the date(s) of renal replacement therapy, death and 
ICU discharge were provided if occurring within the 72 hours after enrollment, as were age, sex, race, weight, 
reason for hospital and ICU admission and medical history. Adjudicators could also request additional information 
for individual patients. The procedures and the precise clinical variables used were finalized prior to the start of 
enrollment and adjudication was completed prior to sample testing and analysis. 
Each adjudicator was provided a form for each patient containing all the clinical information described above and 
identified only by anonymized identification number. Adjudicators indicated their diagnosis (“AKI” or “No AKI”) 
independently without consultation with each other. They had no knowledge of biomarker results at any time. The 
forms were provided to the external statisticians for analysis. 
The diagnosis of AKI was determined by each adjudicator. The basis for the adjudication was the KDIGO consensus 
criteria (based on RIFLE/AKIN definitions for AKI)
E2
 corresponding to stages 2-3 (moderate to severe). The 
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adjudicators were asked to determine whether AKI was present or absent (defined as “AKI” or “no AKI”, 
respectively) within the 12 hours after enrollment and sample collection based on these criteria, but were free to use 
their expert judgment for each case. For example, an adjudicator could diagnose AKI in a patient dying prior to 
reaching KDIGO criteria. A two thirds majority was predefined for use as the final adjudication. 
 
Statistical Analysis 
General analysis: Statistical analyses were performed using SAS 9.2 (SAS Institute, Cary, NC) and R 3.0.
E3
 For all 
analyses, two-sided p-values less than 0.05 or one-sided p-values less than 0.025 were considered statistically 
significant. Categorical variables were analyzed using Fisher Exact test, chi-square test, or logistic regression. All 
performance statistics (area under the ROC curve (AUC), sensitivity, specificity, NPV, PPV, likelihood ratios, and 
relative risk) were calculated as empirical estimates. Logistic regression analyses used the log transform the serum 
creatinine and [TIMP-2]•[IGFBP7] test results.   
Treatment of multiple test results: Each urine sample was measured with the [TIMP-2]•[IGFBP7] test at three 
independent hospital laboratories, resulting in three test values for every subject. For the analysis presented in 
Figures 3 and 4 and Table E4, all three test results were included in a clustered analysis. Confidence intervals were 
calculated using closed-form variance equations for clustered binary data for sensitivity, specificity, NPV and PPV 
and using bootstrap sampling for all other analyses.
E4
 For the analysis presented in Figure 2 and Table 2, the median 
of the three test results was used.   
Multivariate model: The multivariate model shown in Table 2 with clinical risk factors for AKI and the [TIMP-
2]•[IGFBP7] test was constructed in a stepwise process. The first step was to assemble a list of clinical covariates 
that were associated with AKI. This list was assembled as follows: any covariate that was reported to be associated 
(p < 0.1) with AKI by Kashani et al
E5
 (shown in table E4 in Kashani et al) were included; in addition, any of the 
susceptibilities or exposures defined in the KDIGO guideline
E2
 (Table 6 in the KDIGO Guideline) or any covariate 
from Table 1 of the manuscript that was associated (p < 0.1) with the AKI endpoint in the Topaz critically ill cohort 
were included. The second step was to test all of these covariates (Age, BMI, enrollment serum creatinine, 
APACHE excluding renal function assessment, Sex, Race,  history of hypertension, use of nephrotoxic drugs, 
chronic liver disease, diabetes mellitus, history of chronic kidney disease, chronic obstructive pulmonary disease, 
anemia on ICU admission, congestive heart failure, sepsis on ICU admission, major surgery prior to ICU admission, 
cerebrovascular disease on ICU admission) in bivariate models with the [TIMP-2]•[IGFBP7] test result. The third 
step was to construct the multivariate model (Tables 2) with all covariates that had p < 0.1 in the bivariate models 
and that were not components of the non-renal APACHE III score. Three covariates (serum creatinine, body mass 
index and non-renal APACHE III score) met this criterion for inclusion in the multivariate model. 
 
Supplementary Results 
Tables E1 and E2 show analytical characteristics of the clinical assay used to measure TIMP-2 and IGFBP7. Table 
E3 shows a sensitivity analysis of operating characteristics for the [TIMP-2]•[IGFBP7] test over a range of possible 
cutoff values from 0.1 to 2.5 (ng/ml)
2
/1000 for the previously reported Sapphire cohort
E5 
and are the data used to 
predefine the high-sensitivity test cutoff at 0.3 and the high-specificity test cutoff at 2.0 (defined and locked prior to 
measurement of the Topaz validation study samples). Table E4 shows a sensitivity analysis of operating 
characteristics for the Topaz validation study at various cutoff values. 
 
   
Page 32 of 40 AJRCCM Articles in Press. Published on 21-February-2014 as 10.1164/rccm.201401-0077OC 
 Copyright © 2014 by the American Thoracic Society 
7 
 
Tables  
 
Table E1. Analytical sensitivity and reportable range of the clinical assay for the Urinary [TIMP-
2]•[IGFBP7] test (NephroCheck® Test). 
Biomarker 
Limit of 
Blank 
Limit of 
Detection 
Limit of 
Quantitation 
Reportable 
Range 
TIMP-2 0.5 ng/mL 0.7 ng/mL 0.7 ng/mL 1.2–225 ng/mL 
IGFBP7 0.4 ng/mL 2.8 ng/mL 2.8 ng/mL 20–600 ng/mL 
[TIMP-2]•[IGFBP7]/1000 0.0002 0.002 0.002 0.02–135 
 
The limit of blank (LoB), limit of detection (LoD), and limit of quantitation (LoQ) values for each biomarker assay 
contained in the NEPHROCHECK® Test were determined in accordance with the methods provided in CLSI guideline 
EP17-AE6, from measurements conducted with three different lots of test devices. The linearity of the biomarker 
assays contained in the NEPHROCHECK® Test was evaluated in accordance with the methods provided in CLSI 
guideline EP6-AE7 with three different lots of test devices. Assay results were found to be linear between 0.7 and 
284.1 ng/mL for the TIMP-2 assay and 1.0 and 649.8 ng/mL for the IGFBP7 assay, i.e., over the entire reportable 
range. 
 
 
Table E2. Reproducibility of the clinical assay for the urinary [TIMP-2]•[IGFBP7] test (NephroCheck® Test) 
 Biomarker Concentration Total Imprecision (%CV) 
Sample IGFBP7 
(ng/mL) 
TIMP-2 
(ng/mL) 
[TIMP-2]•[IGFBP7] 
(ng/mL)2/1000 
IGFBP7 
(ng/mL) 
TIMP-2 
(ng/mL) 
[TIMP-2]•[IGFBP7] 
(ng/mL)2/1000 
Low 56 2.5 0.14 6.8% 9.3% 13.7% 
Medium 262 122 32 6.2% 4.8% 10.4% 
High 519 195 102 6.1% 5.2% 10.7% 
 
The reproducibility of the concentration results of each individual biomarker, as well as the [TIMP-2]•[IGFBP7] test 
result were determined in accordance with the methods provided in CLSI guideline EP5-A2
E8
.
 
The reproducibility of 
results was determined at three testing sites under intended use conditions using three NEPHROCHECK
®
 Test Kit lots. 
At each site, three urine test samples containing low, medium and high analyte concentrations that spanned the 
measurable range of the test were tested with at least 80 replicates. These data were collected over at least 40 
separate runs that were conducted twice a day over at least 20 total days of testing. The Total Imprecision represents 
the total test variability including within-day, between-day, between-operator and between-device lot variability.  
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Table E3. Operating characteristics (95% CI) as a function of [TIMP-2]•[IGFBP7] test cutoff value for 
discriminating subjects with AKI from subjects with no AKI in the Sapphire cohort of critically ill subjects. 
Cut-off 
((ng/mL)
2
/1000) 
Sensitivity
a
, 
% 
Specificity
a
, 
% 
Negative 
Likelihood 
Ratio
a
 
Positive 
Likelihood 
Ratio
a
 
Negative 
Predictive 
Value
b
, % 
Positive 
Predictive 
Value
b
, % 
0.1 97 (94-100) 22 (20-25) 0.12 (0.00-0.27) 1.25 (1.20- 1.30) 99 (97-100) 14 (13-15) 
0.2 93 (88-97) 38 (35-41) 0.19 (0.07-0.33) 1.50 (1.39- 1.61) 98 (96-99) 16 (15-17) 
0.3 89 (82-94) 50 (47-53) 0.22 (0.11-0.35) 1.79 (1.63- 1.97) 97 (96-99) 18 (17-20) 
0.4 80 (72-87) 58 (54-61) 0.35 (0.23-0.49) 1.89 (1.66- 2.15) 96 (94-97) 19 (17-21) 
0.5 74 (66-82) 65 (62-68) 0.40 (0.27-0.53) 2.12 (1.82- 2.45) 95 (94-97) 21 (18-24) 
0.6 71 (63-80) 71 (68-74) 0.40 (0.28-0.53) 2.50 (2.10- 2.91) 95 (94-97) 24 (21-27) 
0.7 70 (61-79) 76 (73-79) 0.39 (0.28-0.51) 2.92 (2.44- 3.44) 95 (94-97) 27 (23-31) 
0.8 65 (56-74) 80 (77-82) 0.44 (0.32-0.56) 3.17 (2.62- 3.80) 95 (93-96) 29 (25-33) 
0.9 62 (52-71) 82 (79-85) 0.47 (0.36-0.58) 3.43 (2.78- 4.15) 94 (93-96) 30 (26-35) 
1.0 59 (49-69) 84 (82-86) 0.49 (0.37-0.60) 3.67 (2.92- 4.52) 94 (93-95) 32 (27-37) 
1.1 57 (47-67) 86 (83-88) 0.50 (0.38-0.62) 3.97 (3.13- 5.04) 94 (93-95) 33 (28-39) 
1.2 54 (45-64) 87 (85-89) 0.53 (0.42-0.64) 4.17 (3.24- 5.36) 94 (92-95) 34 (29-40) 
1.3 51 (41-60) 88 (86-90) 0.56 (0.45-0.66) 4.39 (3.38- 5.71) 93 (92-95) 36 (30-42) 
1.4 46 (37-56) 90 (88-92) 0.60 (0.49-0.71) 4.54 (3.43- 6.05) 93 (92-94) 36 (30-43) 
1.5 46 (37-56) 91 (89-93) 0.59 (0.49-0.70) 4.99 (3.73- 6.66) 93 (92-94) 39 (32-46) 
1.6 45 (36-55) 92 (90-93) 0.60 (0.49-0.69) 5.39 (4.01- 7.27) 93 (92-94) 40 (34-48) 
1.7 45 (36-54) 93 (91-94) 0.60 (0.50-0.69) 6.08 (4.56- 8.41) 93 (92-94) 43 (36-51) 
1.8 44 (34-53) 94 (92-95) 0.60 (0.50-0.70) 6.82 (5.00- 9.48) 93 (92-94) 46 (38-55) 
1.9 42 (33-52) 94 (93-96) 0.61 (0.51-0.71) 7.16 (5.19-10.09) 93 (92-94) 47 (39-56) 
2.0 42 (33-51) 95 (93-96) 0.62 (0.51-0.71) 7.69 (5.57-10.88) 93 (92-94) 49 (41-58) 
2.1 41 (32-51) 95 (94-96) 0.62 (0.52-0.72) 8.33 (5.96-11.84) 93 (92-94) 51 (43-60) 
2.2 40 (31-50) 96 (94-97) 0.63 (0.53-0.73) 8.96 (6.25-13.08) 93 (91-94) 53 (44-62) 
2.3 38 (29-48) 96 (95-97) 0.64 (0.54-0.74) 9.75 (6.74-14.02) 93 (91-94) 55 (46-64) 
2.4 36 (27-46) 96 (95-97) 0.66 (0.56-0.76) 9.66 (6.43-13.98) 92 (91-93) 55 (45-64) 
2..5 34 (26-44) 96 (95-97) 0.68 (0.59-0.77) 9.56 (6.29-14.12) 92 (91-93) 55 (44-64) 
The operating characteristics show the performance of the [TIMP-2]•[IGFBP7] test for discriminating between 
Sapphire subjects with and without KDIGO Stage 2-3 AKI within 12 hours of sample collection.
5
 These results were 
used to prospectively select the cutoffs validated in the Topaz study, prior to measurement of the Topaz samples. 
a
Sensitivity, specificity and likelihood ratios are operating characteristics that are independent of prevalence of the 
endpoint (AKI), and therefore provide the most consistent estimation of test performance that can be expected across 
different patient cohorts that may have different prevalence of AKI. 
b
Negative and positive predictive values depend 
on the prevalence of the endpoint (AKI) and can be calculated from the test sensitivity and specificity and the 
prevalence. These numbers should be adjusted for the expected prevalence if applied to populations with 
substantially different prevalence.   
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Table E4. Operating characteristics (95% CI) as a function of [TIMP-2]•[IGFBP7] test cutoff value for 
discriminating subjects with AKI from subjects with no AKI in the Topaz cohort of critically ill subjects. 
Cutoff 
((ng/ml)
2
/1000) 
Sensitivity
a
, 
% 
Specificity
a
, 
% 
Negative 
Likelihood 
Ratio
a
 
Positive 
Likelihood 
Ratio
a
 
Negative 
Predictive 
Value
b
, % 
Positive 
Predictive 
Value
b
, % 
0.1   97 (93-100)   14 (11-18) 0.23 (0.03-0.53)   1.1 (1.1-1.2)   95 (91-100)   19 (15-23) 
0.2   94 (88-99)   34 (29-39) 0.18 (0.04-0.36)   1.4 (1.3-1.6)   96 (93-100)   23 (18-28) 
0.3   92 (85-98)   46 (41-52) 0.18 (0.06-0.33)   1.7 (1.5-1.9)   96 (93-99)   27 (21-32) 
0.4   88 (81-95)   55 (50-60) 0.21 (0.09-0.36)   2.0 (1.7-2.3)   96 (93-98)   29 (23-35) 
0.5   84 (75-92)   62 (57-67) 0.26 (0.14-0.41)   2.2 (1.9-2.6)   95 (92-98)   32 (25-38) 
0.6   80 (71-89)   67 (62-72) 0.29 (0.17-0.43)   2.4 (2.0-2.9)   94 (91-97)   34 (27-41) 
0.7   75 (65-85)   70 (66-75) 0.35 (0.22-0.50)   2.5 (2.1-3.1)   93 (90-96)   35 (27-42) 
0.8   73 (62-83)   74 (70-79) 0.37 (0.23-0.52)   2.8 (2.3-3.5)   93 (90-96)   37 (29-45) 
0.9   72 (62-83)   78 (73-82) 0.36 (0.22-0.50)   3.2 (2.5-4.1)   93 (90-96)   41 (32-49) 
1.0   70 (59-80)   82 (78-86) 0.37 (0.24-0.50)   3.9 (3.0-5.1)   93 (90-96)   45 (36-54) 
1.1   66 (55-77)   85 (81-88) 0.40 (0.27-0.53)   4.3 (3.2-5.8)   92 (89-95)   48 (38-57) 
1.2   64 (53-75)   86 (83-90) 0.41 (0.29-0.55)   4.7 (3.4-6.5)   92 (89-95)   50 (40-60) 
1.3   61 (50-72)   88 (85-92) 0.44 (0.32-0.57)   5.3 (3.9-7.6)   91 (88-94)   53 (42-63) 
1.4   58 (47-69)   90 (87-93) 0.47 (0.35-0.59)   5.9 (4.2-8.7)   91 (88-94)   55 (44-66) 
1.5   54 (43-65)   91 (88-94) 0.50 (0.38-0.63)   6.3 (4.3-9.6)   90 (87-93)   57 (45-68) 
1.6   50 (39-61)   92 (90-95) 0.54 (0.42-0.66)   6.6 (4.4-10.2)   90 (87-93)   58 (46-70) 
1.7   47 (36-59)   93 (91-96) 0.56 (0.44-0.69)   6.9 (4.5-11.5)   89 (86-93)   59 (47-72) 
1.8   44 (33-55)   94 (92-96) 0.59 (0.47-0.71)   7.4 (4.7-12.7)   89 (86-92)   61 (48-74) 
1.9   40 (29-51)   94 (92-97) 0.64 (0.52-0.75)   7.1 (4.4-12.4)   88 (85-91)   60 (46-73) 
2.0   37 (26-47)   95 (93-97) 0.67 (0.55-0.78)   7.7 (4.5-14.1)   88 (84-91)   62 (48-76) 
2.1   35 (24-45)   96 (94-98) 0.68 (0.56-0.79)   8.3 (4.9-16.2)   87 (84-91)   64 (49-78) 
2.2   33 (23-44)   96 (94-98) 0.69 (0.58-0.80)   8.8 (5.0-18.0)   87 (84-91)   65 (50-80) 
2.3   31 (21-42)   97 (95-98) 0.71 (0.60-0.81)   9.1 (5.0-18.9)   87 (84-90)   66 (50-81) 
2.4   29 (19-39)   97 (95-99) 0.73 (0.63-0.84)   8.6 (4.6-19.1)   87 (83-90)   65 (48-81) 
2.5   28 (18-38)   97 (95-99) 0.75 (0.64-0.85)   8.7 (4.6-19.4)   86 (83-90)   65 (48-82) 
The operating characteristics show the performance of the [TIMP-2]•[IGFBP7] test for discriminating Topaz 
critically ill subjects with AKI (N = 71) from those with no AKI (N = 337) (see Figure 1 in the manuscript for study 
design). 
a
Sensitivity, specificity and likelihood ratios are operating characteristics that are independent of prevalence 
of the endpoint (AKI), and therefore provide the most consistent estimation of test performance that can be expected 
across different patient cohorts that may have different prevalence of AKI. 
b
Negative and positive predictive values 
depend on the prevalence of the endpoint (AKI) and can be calculated from the test sensitivity and specificity and 
the prevalence. These numbers should be adjusted for the expected prevalence if applied to populations with 
substantially different prevalence.   
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Table E5. Summary of prospective studies of urinary biomarkers of acute kidney injury in critically ill 
patients published before November 2013. 
Urinary 
Biomarker  
Study  AUC (95% CI)  End point  Patients/events Patient population  
[TIMP-
2]•[IGFBP7] 
Bihorac 0.82 (0.76–0.88) Expert adjudicated 
AKI 
408/71 Mixed ICU 
 KashaniE5 0.80 (0.76–0.83) RIFLE I and F 728/101 Mixed ICU 
NGAL  SiewE9  0.71 (0.63–0.78)  AKIN AKI  451/64 Mixed ICU  
 MakrisE10 0.98 (0.82-0.98) RIFLE AKI 31/11 Multi-trauma patients in 
ICU 
 MetzgerE11 0.54 (-)  AKIN AKI  20/9 Mixed ICU  
 MartenssonE12 0.86 (0.68–1.0)  AKIN/RIFLE AKI  45/18 Septic patients in ICU  
 De GeusE13 0.77 (± 0.05) RIFLE AKI  632/171 Mixed ICU  
 EndreE14 0.68 (0.56–0.80) RIFLE AKI  381/27 Mixed ICU  
 KokkorisE15 0.74 (0.64–0.82) RIFLE AKI 100/36 Mixed ICU 
 DoiE16 0.69 (0.63–0.75) RIFLE AKI 339/131 Mixed ICU 
 KashaniE5 0.71 (0.66 – 0.76) RIFLE I and F 728/101 Mixed ICU 
KIM-1 MetzgerE11 0.71 (-)  AKIN AKI 20/9 Mixed ICU  
 EndreE14 0.64 (0.52–0.76) RIFLE AKI 381/27 Mixed ICU  
 KashaniE5 0.69 (0.63 – 0.75) RIFLE I and F 728/101 Mixed ICU 
CyC  NejatE17 0.70 (0.64–0.75) AKIN AKI  444/125 Mixed ICU  
 EndreE14 0.63 (0.51–0.74) RIFLE AKI  381/27 Mixed ICU  
 RoyakkersE18 0.49 (-)  RIFLE AKI  151/35 Mixed ICU  
IL-18  EndreE14 0.72 (0.61–0.83) RIFLE AKI 381/27 Mixed ICU  
 MetzgerE11 0.57 (-)  AKIN AKI 20/9 Mixed ICU  
 SiewE19 0.62 (0.54–0.69)  AKIN AKI  451/64 Mixed ICU  
 ParikhE20 0.73 (-)  AKIN AKI  138/52 Acute lung injury patients 
in ICU   
 DoiE16 0.69 (0.62–0.74) RIFLE AKI 339/131 Mixed ICU 
 KashaniE5 0.76 (0.71 – 0.81) RIFLE I and F 728/101 Mixed ICU 
L-FABP  MatsuiE21 0.95 (-)  AKIN AKI  25/11 Mixed ICU  
 KashaniE5 0.66 (0.60 – 0.72) RIFLE I and F 728/101 Mixed ICU 
 DoiE16 0.75 (0.69–0.79) RIFLE AKI 339/131 Mixed ICU 
α-GST WesthuyzenE22 0.89 (0.69–0.97)  ARF  26/4 Mixed ICU  
 WalsheE23 NRa AKIN AKI  38/19 Septic patients in ICU 
π-GST  WesthuyzenE22  0.93 (0.74–0.99)  ARF  26/4 Mixed ICU  
 WalsheE23  ~0.5 (-)a AKIN AKI  38/19 Septic patients in ICU 
 KashaniE5 0.65 (0.60 – 0.71) RIFLE I and F 728/101 Mixed ICU 
NAG  WesthuyzenE22  0.84 (0.64–0.95)  ARF  26/4 Mixed ICU  
 MatsuiE21  0.63 (-)  AKIN AKI  25/11 Mixed ICU  
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 DoiE16 0.62 (0.56–0.68) RIFLE AKI 339/131 Mixed ICU 
GGT  WesthuyzenE22 0.95 (0.79–0.99)  ARF  26/4 Mixed ICU  
 EndreE14 0.61 (0.49–0.73) RIFLE AKI 381/27 Mixed ICU  
 BlascoE24 0.86 (0.78–0.95) 25% decrease in 
CrCl 
100/36 Mixed ICU 
AP  WesthuyzenE22  0.86 (0.68–0.97)  ARF  26/4 Mixed ICU  
 EndreE14 0.64 (0.52–0.76) RIFLE AKI 381/27 Mixed ICU  
GGTxAP 
indexb 
EndreE25 0.63 (0.52–0.75) RIFLE AKI 345/52 Mixed ICU 
Review of literature additionally included one meta-analysis and five in-depth reviews. 
E26-E31
 
Abbreviations. TIMP-2, tissue inhibitor of metalloproteinases-2; IGFBP7, insulin-like growth factor binding protein 
7; NGAL, Neutrophil gelatinase-associated lipocalin; KIM-1, Kidney injury molecule-1;  CyC, Cystatin C; IL-18, 
Interleukin-18; L-FABP, Liver fatty acid binding protein; α-GST, Alpha-glutathione s-transferase; π-GST, pi-
glutathione s-transferase; NAG, N-acetyl-β-D-glucosaminidase; GGT, Gamma glutanyl transpeptidase; AP, alkaline 
phosphatase. 
a
 Exact AUC nor reported, estimate provided. 
b
 Index is defined as product of GGT and AP > 46.3 units (indexed to urinary creatinine; dimensionless) 
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